Loading...
Found 53 Vision Loss trials
A listing of Vision Loss medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
Sort by:
- Sort by
- Last updated
This is an international, multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD to evaluate the efficacy of lumateperone 42 mg administered once daily compared with placebo as adjunctive treatment to antidepressant therapy
A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults with an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy with Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis
This is an interventional, multi-centre, randomised, parallel group, double-blind, placebo-controlled, comparator-controlled phase 2 study designed to investigate the safety, tolerability and efficacy of different dose-escalation regimens of s.c. NNC0662-0419 in participants living with obesity.
This is a phase-III multi-center double-blind randomized clinical trial of 1,800 individuals with a history of prior preterm birth 35 weeks randomized to either 162 mg aspirin or 81 mg aspirin initiated between 10 and 15 weeks gestation and continued through 36 weeks gestation.
This is a prospective, multicenter, single-blind, randomized (2:1), controlled trial to evaluates the safety and efficacy of the MAGNITUDE S-BRS in the treatment of chronic limb-threatening ischemia due to de novo or restenotic lesions in the infrapopliteal arteries compared to standard PTA alone.
A Phase Ib, randomized, double-blind, placebo-controlled, multi-center, study designed to investigate the responsiveness of a range of cognitive, clinical, biological and digital biomarkers in the CHR population, following 8-weeks of twice-daily oral dosing. The primary focus is to investigate how the selected biomarkers respond to MT1988.
This is an interventional, randomised, multinational, multicentre, two arm parallel-group, double-blind study. The aim of this study is to evaluate the effect of NNC6019-0001 4800 mg versus placebo in participants with variant or wild-type transthyretin (TTR) amyloid cardiomyopathy (ATTRv-CM or ATTRwt-CM, respectively)
This Phase 2b, multicenter, randomized, double-blind, placebo-controlled study evaluates the safety and efficacy of ORKA-001, a biologic targeting IL-23, in adults with moderate-to-severe plaque psoriasis. Participants will undergo screening labs, questionnaires, physical exams, and receive subcutaneous study drug or placebo with regular safety and efficacy assessments.
Double-blind, double-dummy study in adults with CIDP. Patients will be randomized to receive either investigational ARGX-117 and IVIG-placebo OR active standard-of-care IVIG and ARGX-117-placebo. Blood/urine collection, patient-reported outcomes, physician efficacy assessments, ECGs, AEs/ConMeds, and suicidality assessments will be performed.
Clarity is a Phase 3 double-blind, placebo controlled, randomized clinical trial in patients with non-cardioembolic ischemic stroke or high-risk TIA, to determine if the addition of cilostazol to standard-of-care aspirin or clopidogrel reduces major adverse cardiovascular events during long term follow-up
Please choose between Voice or SMS based delivery of verification code
or